{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:42:29Z","timestamp":1788270149042,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypomagnesemia frequently occurs after kidney transplantation, potentially contributing to morbidity. Sodium-glucose co-transporter 2 inhibitors (SGLT2i), such as dapagliflozin, have proven benefits in chronic kidney disease, but their effects on serum magnesium in non-diabetic transplant recipients remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively studied 122 adult kidney-transplant recipients who initiated dapagliflozin between September 2020 and July 2023. We obtained two serum samples: one before and one after dapagliflozin initiation in 94 patients. After excluding patients with inadequate sampling or early discontinuation, 34 patients were analyzed and compared with 96 controls not receiving dapagliflozin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, hypomagnesemia was present in 26.5% of dapagliflozin-treated patients and 22.9% of controls. After a median of 8.1 months on dapagliflozin, serum magnesium increased significantly (P = .00018), correcting hypomagnesemia in 7 of 9 affected patients. No significant change occurred in the control group. Serum phosphate also significantly increased (P = .026), while estimated glomerular filtration rate (eGFR) declined (P = .0001), consistent with known hemodynamic effects of SGLT2i. No significant variations in magnesium, phosphate, or eGFR were observed among controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this cohort, dapagliflozin use was associated with improved serum magnesium in kidney-transplant recipients, particularly those with baseline hypomagnesemia, thus warranting further prospective investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajag046","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:33:54Z","timestamp":1770726834000},"page":"582-590","source":"Crossref","is-referenced-by-count":1,"title":["Dapagliflozin corrects hypomagnesemia in kidney-transplant patients"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8659-5908","authenticated-orcid":false,"given":"Douchka","family":"Guillot","sequence":"first","affiliation":[{"name":"Center for Research in Transplantation and Translational Immunology, Nantes Universit\u00e9, CHU Nantes, INSERM, UMR 1064, ITUN , Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dejoie","sequence":"additional","affiliation":[{"name":"Biochemestry Laboratory, Nantes University Hospitals , Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Kerleau","sequence":"additional","affiliation":[{"name":"Center for Research in Transplantation and Translational Immunology, Nantes Universit\u00e9, CHU Nantes, INSERM, UMR 1064, ITUN , Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Walencik","sequence":"additional","affiliation":[{"name":"Histocompatibility Laboratory, Etablissement Fran\u00e7ais du Sang , Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Dantal","sequence":"additional","affiliation":[{"name":"Center for Research in Transplantation and Translational Immunology, Nantes Universit\u00e9, CHU Nantes, INSERM, UMR 1064, ITUN , Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Maillard","sequence":"additional","affiliation":[{"name":"Center for Research in Transplantation and Translational Immunology, Nantes Universit\u00e9, CHU Nantes, INSERM, UMR 1064, ITUN , Nantes ,","place":["France"]},{"name":"Centers for Rare Diseases Fili\u00e8re OSCAR and Fili\u00e8re ORKID, Nantes University Hospital , Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Legouis","sequence":"additional","affiliation":[{"name":"Division of Intensive Care Medicine, Department of Acute Care Medicine, Geneva University Hospitals , Geneva ,","place":["Switzerland"]},{"name":"Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Faculty of Medicine, University of Geneva , Geneva ,","place":["Switzerland"]},{"name":"Laboratory of Renal Cells, Department of Physiology and Cell Metabolism, University of Geneva , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-2064","authenticated-orcid":false,"given":"Lucile","family":"Figueres","sequence":"additional","affiliation":[{"name":"Center for Research in Transplantation and Translational Immunology, Nantes Universit\u00e9, CHU Nantes, INSERM, UMR 1064, ITUN , Nantes ,","place":["France"]},{"name":"Centers for Rare Diseases Fili\u00e8re OSCAR and Fili\u00e8re ORKID, Nantes University Hospital , Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"2026073019523178500_aajag046-B1","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.3390\/ijms26136528","article-title":"Prevalence, risk factors and potential protective strategies for hypomagnesemia in kidney transplant recipients","volume":"26","author":"Riaza Ortiz","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026073019523178500_aajag046-B2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40620-014-0140-6","article-title":"Magnesium in CKD: more than a calcification inhibitor?","volume":"28","author":"Floege","year":"2015","journal-title":"J Nephrol"},{"key":"2026073019523178500_aajag046-B3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1681\/ASN.2017080849","article-title":"Magnesium and risk of hip fracture among patients undergoing hemodialysis","volume":"29","author":"Sakaguchi","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2026073019523178500_aajag046-B4","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"N Engl J Med"},{"key":"2026073019523178500_aajag046-B5","doi-asserted-by":"publisher","first-page":"110200","DOI":"10.1016\/j.diabres.2022.110200","article-title":"SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: a population-based propensity score-matched cohort study","volume":"195","author":"Chan","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2026073019523178500_aajag046-B6","doi-asserted-by":"publisher","first-page":"e00247","DOI":"10.1002\/edm2.247","article-title":"Canagliflozin, serum magnesium and cardiovascular outcomes-analysis from the CANVAS program","volume":"4","author":"Wang","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"key":"2026073019523178500_aajag046-B7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.34067\/KID.0006672021","article-title":"Comparative effects of sodium-glucose cotransporter 2 inhibitors on Serum electrolyte levels in patients with type 2 diabetes: a pairwise and network meta-analysis of randomized controlled trials","volume":"3","author":"Zhang","year":"2022","journal-title":"Kidney360"},{"key":"2026073019523178500_aajag046-B8","doi-asserted-by":"publisher","first-page":"107402","DOI":"10.1016\/j.jdiacomp.2019.06.007","article-title":"Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: a post hoc analysis of 10 randomized, placebo-controlled trials","volume":"33","author":"Toto","year":"2019","journal-title":"J Diabetes Complications"},{"key":"2026073019523178500_aajag046-B9","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials","volume":"59","author":"Tang","year":"2016","journal-title":"Diabetologia"},{"key":"2026073019523178500_aajag046-B10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s10157-024-02590-8","article-title":"SGLT2 inhibitors increase low serum magnesium levels in patients with chronic kidney disease immediately after treatment","volume":"29","author":"Osawa","year":"2025","journal-title":"Clin Exp Nephrol"},{"key":"2026073019523178500_aajag046-B11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.xkme.2020.01.010","article-title":"SGLT2 inhibitors for treatment of refractory hypomagnesemia: a case report of 3 patients","volume":"2","author":"Ray","year":"2020","journal-title":"Kidney Med"},{"key":"2026073019523178500_aajag046-B12","doi-asserted-by":"publisher","first-page":"100697","DOI":"10.1016\/j.xkme.2023.100697","article-title":"SGLT2 inhibitors in management of severe hypomagnesemia in patients without diabetes: a report of 4 cases","volume":"5","author":"Shah","year":"2023","journal-title":"Kidney Med"},{"key":"2026073019523178500_aajag046-B13","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.3390\/ijms26072904","article-title":"Impact of SGLT2 inhibitors on magnesium in kidney transplant patients with and without diabetes","volume":"26","author":"Secondulfo","year":". 2025","journal-title":"Int J Mol Sci"},{"key":"2026073019523178500_aajag046-B14","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/ckj\/sfad007","article-title":"Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study","volume":"16","author":"S\u00e1nchez Fructuoso","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026073019523178500_aajag046-B15","doi-asserted-by":"publisher","first-page":"101175","DOI":"10.1016\/j.bonr.2022.101175","article-title":"Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes\u2014data from a randomized, placebo-controlled study","volume":"16","author":"Rau","year":"2022","journal-title":"Bone Rep"},{"key":"2026073019523178500_aajag046-B16","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1681\/ASN.2022050623","article-title":"Treatment effect of the SGLT2 inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crossover trial","volume":"34","author":"Refardt","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2026073019523178500_aajag046-B17","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026073019523178500_aajag046-B18","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes Mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"2026073019523178500_aajag046-B19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12011-011-9178-7","article-title":"Effect of mycophenolate mofetil on plasma bioelements in renal transplant recipients","volume":"145","author":"Kami\u0144ska","year":"2012","journal-title":"Biol Trace Elem Res"},{"key":"2026073019523178500_aajag046-B20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10157-022-02277-y","article-title":"Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus","volume":"27","author":"Shibata","year":"2023","journal-title":"Clin Exp Nephrol"},{"key":"2026073019523178500_aajag046-B21","doi-asserted-by":"publisher","first-page":"e13846","DOI":"10.1111\/apha.13846","article-title":"Mechanisms of proton pump inhibitor-induced hypomagnesemia","volume":"235","author":"Gommers","year":"2022","journal-title":"Acta Physiol"},{"key":"2026073019523178500_aajag046-B22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/ndt\/gfl817","article-title":"Ciclosporin reduces paracellin-1 expression and magnesium transport in thick ascending limb cells","volume":"22","author":"Chang","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2026073019523178500_aajag046-B23","doi-asserted-by":"publisher","first-page":"F486","DOI":"10.1152\/ajprenal.00116.2011","article-title":"Expression of renal distal tubule transporters TRPM6 and NCC in a rat model of cyclosporine nephrotoxicity and effect of EGF treatment","volume":"301","author":"Ledeganck","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026073019523178500_aajag046-B24","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1681\/ASN.0000000700","article-title":"SGLT2 inhibitors blunt kidney magnesium wasting in acute cisplatin-induced hypomagnesemia with effects on the thick ascending limb and distal convoluted tubule","volume":"36","author":"Jesus","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026073019523178500_aajag046-B25","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1016\/j.ekir.2025.07.035","article-title":"Novel RRAGD variants in autosomal dominant kidney hypomagnesemia and therapeutic perspectives","volume":"10","author":"Adella","year":"2025","journal-title":"Kidney Int Rep."},{"key":"2026073019523178500_aajag046-B26","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41598-022-05704-y","article-title":"The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes","volume":"12","author":"Okura","year":"2022","journal-title":"Sci Rep"},{"key":"2026073019523178500_aajag046-B27","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1681\/ASN.0000000000000092","article-title":"The effect of magnesium supplementation on vascular calcification in CKD: a randomized clinical trial (MAGiCAL-CKD)","volume":"34","author":"Bressendorff","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2026073019523178500_aajag046-B28","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1093\/ndt\/gfq728","article-title":"The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients","volume":"26","author":"Van Laecke","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2026073019523178500_aajag046-B29","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1159\/000510797","article-title":"Posttransplantation hypomagnesemia as a predictor of better graft function after transplantation","volume":"45","author":"Hod","year":"2020","journal-title":"Kidney Blood Press Res"},{"key":"2026073019523178500_aajag046-B30","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1097\/TP.0000000000005496","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists in kidney transplantation: a systematic review and meta-analysis","volume":"110","author":"Lee","year":"2025","journal-title":"Transplantation"},{"key":"2026073019523178500_aajag046-B31","doi-asserted-by":"publisher","first-page":"F227","DOI":"10.1152\/ajprenal.00298.2022","article-title":"Magnesium reabsorption in the kidney","volume":"324","author":"de Baaij","year":"2023","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/3\/582\/68374292\/aajag046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/3\/582\/68374292\/aajag046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:52:38Z","timestamp":1785455558000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/3\/582\/8691469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,23]]},"published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag046","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,4]]}}}